Title of article
Metformin and Intravascular Contrast Media: What to do in Patients Receiving Both: a Narrative Review
Author/Authors
Shams, Moghadaseh Department of Imaging - Taleghani Hospital - Shahid Beheshti University of Medical Sciences, Tehran , Dehghan, Pooneh Taleghani Hospital Research Development Center - Shahid Beheshti University of Medical Sciences, Tehran , Hosseinpanah, Farhad Obesity Research Center - Research Institute for Endocrine Sciences - Shahid Beheshti University of Medical Sciences, Tehran
Pages
8
From page
138
To page
145
Abstract
Metformin-associated lactic acidosis (M-ALA) is considered to be one of the complications caused by intravascular contrast media (CM) administration in diabetics especially those with coexisting renal or cardiac impairment. We focused on the necessity and duration of metformin suspension in diabetics with normal or impaired renal function scheduled for CT scan with IV contrast. Searching PubMed, Web of Science, and Scopus databases, we reviewed the latest relevant guidelines as well as articles published from 1994 to 2015. There is no global consensus among different guidelines on the duration of the Metformin suspension before CT scan with IV contrast. Also, lack of substantial evidence supporting M-ALA encourages specialists to take a less conservative approach.
It is safe to continue Metformin in patients with normal renal function who have no co-morbidities. In cases of equivocal renal function (30
Keywords
Metformin , Lactic acidosis , Contrast media , CT scan
Journal title
Astroparticle Physics
Serial Year
2017
Record number
2447138
Link To Document